Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytek Biosciences, Inc. (Nasdaq: CTKB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer on the Nasdaq Global Select Market. These documents help investors and analysts understand Cytek’s financial condition, operating results and governance as a cell analysis solutions company focused on Full Spectrum Profiling™ (FSP®) flow cytometry instruments, reagents and services.
Cytek submits Form 10-Q quarterly reports and Form 10-K annual reports, which include details on revenue from products, services and reagents, gross margins, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as information on cash and marketable securities. These filings also discuss risk factors, market conditions and other elements relevant to its analytical laboratory instrument manufacturing business.
The company also files Form 8-K current reports to disclose material events. Recent 8-K filings have covered quarterly financial results under Item 2.02 (Results of Operations and Financial Condition) and outcomes of the annual meeting of stockholders under Item 5.07, including votes on director elections, executive compensation and ratification of the independent registered public accounting firm.
In addition, investors can review exhibits attached to these filings, such as press releases furnished as Exhibit 99.1, which provide narrative context for the numbers reported. Over time, the filings record Cytek’s progress in areas such as recurring revenue growth from services and reagents, expansion of its installed instrument base and capital allocation decisions.
On Stock Titan, Cytek’s SEC filings are updated in near real time from the EDGAR system. AI-powered summaries highlight key points from lengthy 10-K and 10-Q reports, and help users quickly identify information on revenue composition, operating trends and risk disclosures. The page also makes it easier to locate Form 4 and other insider-related filings when available, supporting research into trading activity and governance practices at CTKB.
Cytek Biosciences, Inc. director and chief technology officer Yan Ming reported a bona fide gift of 1,176,000 shares of Common Stock. The transfer carried a reported price of $0.00 per share, reflecting that it was a non-cash gift, not a market sale. After this disposition, Ming’s direct holdings are reported at 4,915,933 Common Stock shares, indicating he retains a substantial ownership position in the company.
Cytek Biosciences director Richard Chin exercised restricted stock units into common shares. On this date, 6,107 Restricted Stock Units converted into 6,107 shares of common stock at no exercise price. After the transaction, he directly holds 16,285 shares of common stock and 57,004 Restricted Stock Units.
The footnotes explain that each RSU represents a contingent right to one share of common stock and describe a multi‑date vesting schedule, with portions of the award vesting on specified dates in August, November, March, and May until fully vested.
Cytek Biosciences, Inc. Chief Legal Officer Valerie Barnett reported equity compensation and vesting activity. She received a stock option grant for 120,114 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. She was also granted 226,453 restricted stock units (RSUs) that vest over four years on specified May, August, November, and March dates. On the same date, several earlier RSU awards vested, converting a total of 29,722 RSUs into common shares. Of these, 11,748 shares were withheld at $4.23 per share to cover tax obligations, and the remainder increased her directly held common stock to 134,436 shares. These are compensation-related grants, exercises, and tax withholdings rather than open‑market purchases or sales.
Cytek Biosciences SVP Philippe Busque reported equity compensation and vesting activity. On March 10, 2026 he received an employee stock option for 70,665 shares of common stock at an exercise price of $4.23 per share, vesting monthly over four years. He was also granted 133,226 restricted stock units, each representing one share of common stock, scheduled to vest over four years under specified annual dates.
On the same date, several existing RSU awards vested, leading to the issuance of 9,828 shares of common stock through derivative exercises, while 3,043 shares were withheld by the company at $4.23 per share to cover tax obligations. Following these transactions, Busque directly held 35,687 shares of common stock.
Cytek Biosciences President and CEO Wenbin Jiang reported several equity compensation transactions. He was granted an employee stock option for 485,545 shares of common stock at an exercise price of
On the same date, previously granted RSUs vested and were converted into common stock in tranches of 15,708, 29,467, and 38,669 shares. To satisfy tax withholding obligations from these vestings, 3,825, 7,747, and 9,416 shares of common stock were surrendered back to the company at
Cytek Biosciences Chief Financial Officer William D. McCombe reported new equity awards and routine vesting-related activity. He received an employee stock option for 136,205 shares of common stock at an exercise price of
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported several equity compensation transactions. On
Ming exercised previously granted RSUs covering a total of 25,400 shares of common stock. Of the resulting shares, 7,731 shares were withheld and surrendered to Cytek Biosciences at
Cytek Biosciences director Michael Holder reported the vesting and exercise of restricted stock units into common shares as part of his equity compensation. On March 10, 2026, 2,908 RSUs converted into 2,908 shares of common stock at no cash cost, lifting his directly held common stock to 15,267 shares after the transaction.
Cytek Biosciences reports 2025 results and outlines its strategy as a leading cell analysis solutions provider built around its patented Full Spectrum Profiling (FSP) flow cytometry technology. The company sells Aurora, Northern Lights, Aurora Evo and Aurora CS instruments, reagents, software and services to pharma, biotech, CROs and academic labs worldwide.
Revenue was $201.5 million in 2025, up slightly from $200.5 million in 2024 and $193.0 million in 2023, while the net loss widened to $66.5 million from $6.0 million in 2024 and $12.1 million in 2023. Cash, cash equivalents, restricted cash and short-term investments totaled $261.5 million as of December 31, 2025.
The filing highlights new products such as the Aurora Evo system, Enhanced Small Particle detection, the Muse Micro analyzer and expansion of manufacturing in China and Singapore. Cytek emphasizes recurring consumables, software ecosystems like Cytek Cloud, clinical applications, global scale and an intellectual property portfolio protecting its FSP platform.
Cytek Biosciences reported modest 2025 revenue growth but a sharp drop in profitability and issued cautious 2026 guidance. Full-year 2025 revenue was $201.5 million, up 1% from 2024, with product revenue down and service revenue up.
GAAP gross margin fell to 52% from 55%, and operating expenses rose 10% to $144.8 million, driven mainly by higher general and administrative costs. The company posted a 2025 net loss of $66.5 million versus a $6.0 million loss in 2024, largely due to higher expenses and a non-cash deferred tax valuation allowance.
Adjusted EBITDA dropped to $5.0 million from $22.4 million, and cash and marketable securities declined to $261.5 million as of December 31, 2025, partly reflecting a $15.1 million share repurchase. For 2026, Cytek guides revenue to $205–$212 million, implying 2–5% growth.